'Vascular death' presentation slideshows

Vascular death - PowerPoint PPT Presentation

The results of the SHARP trial

The results of the SHARP trial

The results of the SHARP trial. SHARP: Rationale. Risk of vascular events is high among patients with chronic kidney disease Lack of clear association between cholesterol level and vascular disease risk Pattern of vascular disease is atypical, with a large proportion being non-atherosclerotic

★ ★ ★ ★ ★

536 views • 29 slides
ACTIVE A

ACTIVE A

ACTIVE A. Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists. Disclosures. The presenter has the following relationships: Research grants from, Portola, AstraZeneca, Boston Scientific, St. Jude Medical

★ ★ ★ ★ ★

390 views • 27 slides
Presenter Disclosure Information

Presenter Disclosure Information

Presenter Disclosure Information. Stuart J. Connolly The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE). DISCLOSURE INFORMATION: The following relationships exist related to this presentation:

★ ★ ★ ★ ★

436 views • 27 slides
Why Are We Invloved in the Detection and Treatment of Peripheral Artery Disease ?

Why Are We Invloved in the Detection and Treatment of Peripheral Artery Disease ?

Why Are We Invloved in the Detection and Treatment of Peripheral Artery Disease ?. HU Dayi. Major Clinical Manifestations of Atherothrombosis. Ischemic stroke. Transient ischemic attack. Myocardial infarction. Angina. Renal artery stenosis. Atherosclerotic nephrology.

★ ★ ★ ★ ★

283 views • 18 slides
Amjad AlMahameed, MD Director, Vascular Medicine Research

Amjad AlMahameed, MD Director, Vascular Medicine Research

Medical Management of Claudication: Just Walk it Off!!. Amjad AlMahameed, MD Director, Vascular Medicine Research Associate Staff, Section of Vascular Medicine Department of Cardiovascular Medicine Cleveland Clinic Foundation. Objectives.

★ ★ ★ ★ ★

331 views • 17 slides
ESPS-2: European Stroke Prevention Study

ESPS-2: European Stroke Prevention Study

Multicentre, randomized, double-blind, placebo-controlled trial 6,602 patients randomized within 3 months of qualifying event (TIA or stroke) Treatment and follow-up time: 2 years Visits at 1 month and 3 months, then at 3-month intervals. ESPS-2: European Stroke Prevention Study .

★ ★ ★ ★ ★

892 views • 16 slides
ASSERT Healey et al NEJM 2012;366(2):120

ASSERT Healey et al NEJM 2012;366(2):120

RAJ CHAHAL 31/01/2012. ASSERT Healey et al NEJM 2012;366(2):120. http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105575. Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT).

★ ★ ★ ★ ★

264 views • 10 slides
Lancet 2008 371 : 117-125 doi:10.1016/S0140-6736(08)60104-X

Lancet 2008 371 : 117-125 doi:10.1016/S0140-6736(08)60104-X

Efficacy of cholesterol-lowering therapy in 18,868 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 371 : 117-125 doi:10.1016/S0140-6736(08)60104-X. Baseline characteristics of participants with diabetes (1).

★ ★ ★ ★ ★

233 views • 10 slides

View Vascular death PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Vascular death PowerPoint presentations. You can view or download Vascular death presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.